Gene therapy that induces the body to create microRNA-22 (miR-22), a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma, the most common form of liver cancer.
The miR-22 treatment also reduced liver inflammation and produced better survival outcomes with no observable toxicity compared to the FDA-approved liver cancer treatment lenvatinib.
Those are the findings of a new study from the UC Davis Comprehensive Cancer Center published in Molecular Therapy.
“This research introduces miR-22 gene therapy as a promising and innovative approach for treating hepatocellular carcinoma,” said Yu-Jui Yvonne Wan, senior author of the study.
Wan is a distinguished professor and vice chair for research in the UC Davis Department of Pathology and Laboratory Medicine.
“The study's findings suggest that miR-22 therapy could provide better survival outcomes, enhance anti-tumour immunity, improve metabolism and reduce inflammation.”
The University of California filed a patent application for Wan’s discovery of miR-22 for treating hepatic and metabolic diseases.
The patent is currently pending.
MicroRNAs are small molecules that contain ribonucleic acid (RNA), a type of genetic material.
MicroRNAs are widely found in plants and animals.
They are “non-coding,” meaning they do not make proteins like some other RNA molecules.
In the case of miR-22, it acts like a brake, stopping the production of certain proteins, including cyclin A, protein deacetylases and hypoxia-inducible factor, that can fuel liver cancer growth.
A lack of miR-22 is found in hepatocellular carcinoma tumours, and its levels can predict survival time for patients with the disease.
Wan studies the interaction between gut microbes and the liver, what’s known as the gut-liver axis.
Her previous research shows that metabolites produced by the gut microbiome help create miR-22 and have anti-cancer benefits.
These metabolites include retinoic acid, short-chain fatty acids, bile acids and vitamin D3.
When people have colon or liver cancer, signalling from these metabolites is reduced, which in turn reduces miR-22.
This was a clue for Wan that returning miR-22 to a higher level might act as a treatment for liver cancer.
She launched several studies, including one demonstrating miR-22 could suppress liver tumours by targeting both liver and immune cells.
For this study, Wan and first author Ying Hu, an assistant professional researcher in Wan’s lab, turned to gene therapy.
Using an inactivated adenovirus, they introduced miR-22 into the mice with a single intravenous injection.
The mice treated with the gene therapy were compared with mice treated with the current FDA-approved drug lenvatinib (administered orally once a day), untreated mice and healthy mice.
Both miR-22 and lenvatinib inhibited the progression of the liver cancer compared to untreated mice.
However, the miR-22-treated mice had longer survival times without toxicity compared with lenvatinib-treated mice.
Some of the study’s key findings:
According to the American Cancer Society, liver cancer is a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year.
In the United States, each year about 25,000 men and 11,000 women are diagnosed with liver cancer, while 19,000 men and 9,000 women die from the disease.
Risk factors for liver cancer include long-term hepatitis B or hepatitis C infections, obesity, non-alcoholic fatty liver disease, excess alcohol consumption, auto-immune liver disease and exposure to aflatoxins (a toxin found in mouldy peanuts or grains).
Hepatocellular carcinoma is becoming a bigger problem due to rising obesity rates worldwide, including in the US.
Drugs to treat hepatocellular carcinoma — sorafenib, lenvatinib, regorafenib, andcabozantinib — are associated with considerable toxicities and poor quality-of-life outcomes.
The survival benefit is limited to a few months and the cost is very high.
"The positive findings from this preclinical study give us hope that miR-22 could be a promising alternative to treat hepatocellular carcinoma,” Hu said.
Additional authors include Tahereh Setayesh, Farzam Vaziri, Xuesong Wu and Samuel T Hwang from the University of California, Davis.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.